Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, United States.
Front Immunol. 2019 Feb 15;10:218. doi: 10.3389/fimmu.2019.00218. eCollection 2019.
Immunotherapy with chimeric antigen receptor (CAR) T cells offers a promising method to improve cure rates and decrease morbidities for patients with cancer. In this regard, CD19-specific CAR T cell therapies have achieved dramatic objective responses for a high percent of patients with CD19-positive leukemia or lymphoma. Most patients with solid tumors however, have experienced transient or no benefit from CAR T cell therapies. Novel strategies are therefore needed to improve CAR T cell function for patients with solid tumors. One obstacle for the field is limited CAR T cell persistence after infusion into patients. In this review we highlight genetic engineering strategies to improve CAR T cell persistence for enhancing antitumor activity for patients with solid tumors.
嵌合抗原受体 (CAR) T 细胞免疫疗法为提高癌症患者的治愈率和降低发病率提供了一种很有前途的方法。在这方面，针对 CD19 的 CAR T 细胞疗法已经使很大比例的 CD19 阳性白血病或淋巴瘤患者获得了显著的客观缓解。然而，大多数实体瘤患者从 CAR T 细胞治疗中仅获得短暂获益或无获益。因此，需要新的策略来提高 CAR T 细胞在实体瘤患者中的功能。该领域的一个障碍是 CAR T 细胞输注到患者体内后的持久性有限。在这篇综述中，我们强调了基因工程策略，以提高 CAR T 细胞的持久性，从而增强实体瘤患者的抗肿瘤活性。
